SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Checkpoint Therapeutics, Inc. - CKPT
NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Checkpoint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On December 18, 2023, Checkpoint issued a press release "announc[ing] that the U.S. Food and Drug Administration ('FDA') has issued a complete response letter ('CRL') for the cosibelimab biologic license application ('BLA') for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma ('cSCC') who are not candidates for curative surgery or radiation. The CRL only cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party contract manufacturing organization as approvability issues to address in a resubmission." The Company's President and Chief Executive Officer stated that "we believe we can address the feedback in a resubmission to enable marketing approval in 2024".
On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article